• Policy
• 1 ‘Soliris’ and 4 ‘Ultomiris’ cases seek prior approval
• by Lee, Hye-Kyung Feb 7, 2022 05:57am

• Policy
• Janssen Korea has obtained permission
• by Lee, Tak-Sun Feb 4, 2022 05:56am

• Policy
• 45 generics of Dapagliflozin+Sitagliptin were approved
• by Lee, Tak-Sun Feb 3, 2022 05:57am

• Policy
• Publicized discussion on PAH reimbursement bears fruit
• by Choi-sun Jan 28, 2022 05:57am

• Policy
• Generics for Galvus will be listed next month
• by Kim, Jung-Ju Jan 28, 2022 05:57am

• Policy
• MNCs ask to “Innovate new drug reimbursement environment"
• by Lee, Jeong-Hwan Jan 27, 2022 05:43am

• Policy
• PVA guidelines are about to be revised
• by Lee, Hye-Kyung Jan 27, 2022 05:43am

• Policy
• The NHIS will begin research on improving the PVA system
• by Lee, Jeong-Hwan Jan 27, 2022 05:43am

• Policy
• PVA price reduction needs to be improved
• by Lee, Jeong-Hwan Jan 26, 2022 05:57am

• Policy
• The presidential candidate's pledge to expand NIP is fierce
• by Lee, Jeong-Hwan Jan 26, 2022 05:57am